Keith Regnante - 18 Feb 2026 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Signature
/s/ Keith Regnante
Issuer symbol
KROS
Transactions as of
18 Feb 2026
Net transactions value
-$77,483
Form type
4
Filing time
20 Feb 2026, 16:15:07 UTC
Previous filing
19 Feb 2025
Next filing
26 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Regnante Keith CHIEF FINANCIAL OFFICER C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON /s/ Keith Regnante 20 Feb 2026 0001682068

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Sale $77,483 -4,739 -11% $16.35 39,261 18 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.